Fischer K, et al. - In previously untreated patients with chronic lymphocytic leukemia (CLL) and comorbidities, researchers compared fixed-duration targeted venetoclax plus obinutuzumab (VenG) treatment with chlorambucil-obinutuzumab (ClbG) treatment. In this multinational, open-label, phase 3 CLL14 trial, they presented endpoint analyses focusing on progression-free survival (PFS) and minimal residual disease (MRD)-negativity. Participants in the study were 432 patients (216 in each treatment group; intent-to-treat population). Findings revealed that fixed-duration VenG induced deep, high (<10^-4 in 3/4 of patients and <10^-6 in 1/3 of patients), and long lasting MRD-negativity rates (with a low rate of conversion to MRD-positive status 1 year after treatment) in previously untreated patients with CLL and comorbidities, resulting in improved PFS.